S
Shift Bioscience
Biotech & Life Sciences · Cambridge, United Kingdom · Founded 2017
Shift Bioscience is unlocking safe rejuvenation with cell simulations MoreLess
Shift Bioscience is a biotechnology company that develops drugs to reprogram mitochondrial DNA mutations to address age-related diseases. The company has a cell simulation platform that uses generative AI and a proprietary biological aging clock to predict which gene sets are most likely to be effective in reversing cellular aging. This platform allows them to discover and develop new therapies for a range of age-driven conditions.
Shift Bioscience operates in the biotechnology and longevity market, targeting the significant and growing demand for treatments for age-related diseases. The company's business model is centered around research and development, with the ultimate goal of commercializing its therapies. They have raised $28.6M in funding over 7 rounds from 19 investors, which indicates strong investor confidence in their approach.
Keywords: biotechnology, cellular rejuvenation, mitochondrial DNA, generative AI, aging clock, drug development, age-related diseases, longevity, therapies, genetics
Company overview
Shift Bioscience company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2017
- Headquarters
- Cambridge, United Kingdom
- Employees
- 24
- Open positions
- None listed
- Dealroom signal
- 69.0
Valuation & funding
Shift Bioscience funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| GRANT✓Other financing | Apr 2025 | $459K | — | UK Research and Innovation | — |
| SEED✓Equity / VC | Oct 2024 | $16M | $64M | Jonathan Milner · F-Prime · Business Growth Fund · Kindred Capital | ↗ |
| SEED✓Equity / VC | Jan 2022 | $0 | — | Kindred Capital · F-Prime | — |
Financials
Revenue and workforce over time
Available revenue and workforce history. Fields without reported data are omitted.
| Year | Revenue | Growth | Employees |
|---|---|---|---|
| 2026 | $825K | 0% | 24 |
| 2025 | $825K | 0% | 25 |
| 2024 | $825K | 0% | 16 |
| 2023 | $825K | +106.3% | 11 |
| 2022 | $400K | — | 11 |
Growth signals
Shift Bioscience website traffic
Latest recorded traffic for Shift Bioscience is 2.8K monthly website visits, up 33.3% over the last three months. Shift Bioscience's team declined 4% over the past year.
Comparisons
Shift Bioscience compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
Shift Bioscience's talent
Source: Dealroom Talent Intelligence.
Global footprint
Where Shift Bioscience has talent and traffic
team presence
In the news
Latest news about Shift Bioscience
Recent press, funding announcements, and product moves mentioning Shift Bioscience — open to read from the original sources.
Market sentiment
What the market is saying about Shift Bioscience
An AI-synthesized read of the highest-engagement posts about Shift Bioscience on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Shift Bioscience’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.